By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Biogen Idec, Inc. (Massachusetts) 

225 Binney Street

Cambridge  Massachusetts  02142  U.S.A.
Phone: 781-464-2000 Fax: n/a


SEARCH JOBS

Biogen Idec (NASDAQ: BIIB) is a biotechnology leader that discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. With its rich scientific heritage and passionate commitment to pioneering new advances, Biogen Idec recognizes that cutting-edge science and medicines can address unmet patient needs to change the course of devastating diseases.

Founded in 1978, Biogen Idec is the world’s oldest independent biotechnology company. Patients worldwide benefit from its leading multiple sclerosis therapies, and the company generates nearly $5 billion in annual revenues. Biogen Idec has a strong late stage pipeline with the potential to launch new products for multiple sclerosis, amyotrophic lateral sclerosis (ALS) and hemophilia by 2015.

With about 4,800 employees worldwide, Biogen Idec is a truly global organization. In addition to our headquarters in Weston, Mass., and our research operations in Cambridge, Mass., we have a world-class manufacturing facility in North Carolina and offices in Canada, Australia, Japan and throughout Europe. We also have a direct commercial presence in more than 29 markets and a network of distribution partners in more than 70 additional markets, including new markets such as Central/Eastern Europe, Brazil, China and India.

For product labeling, press releases and additional information about the company, please visit www.biogenidec.com

YEAR FOUNDED:

1978

LEADERSHIP:

CEO: George A. Scangos, PhD

CMO: Alfred W. Sandrock, Jr., M.D., PhD

CFO: Paul J. Clancy

JOB OPPORTUNITY:

Please click here for Biogen job opportunities..

CLINICAL TRIAL:

Please click here for clinical trial information.

PRODUCTS:

Please click here for product information..

FOLLOW BIOGEN:




Key Statistics


Email:
Ownership: Public

Web Site: Biogen
Employees: 1700
Symbol: BIIB
 



Industry
Biotechnology


Collaborations

NeoGenesis Pharmaceuticals, Inc.  Small molecule High Throughput Screening for multiple programs (6/01)

GPC Biotech, Inc.  HIV TAT-derived transport polytptides and methods of their use (5/01) - this was an outlicense from a research

ICOS Corporation  LFA-1 small molecule for psoriasis (7/01)

Elan  (crohn's & MS)

Dyax  Antibody phage display

Dow AgroSciences LLC 

Sigma-Aldrich 

Sangamo 

Shire 





Company News
Celgene (CELG) Could Dethrone Biogen (BIIB) in Multiple Sclerosis 9/29/2016 6:48:04 AM
Biogen (BIIB) Forges Deal to Test Anavex (AVXL)'s Lead Drug Candidate 9/28/2016 6:07:25 AM
Biogen (BIIB) Completes Rolling Submission Of New Drug Application To FDA For Nusinersen As A Treatment For Spinal Muscular Atrophy 9/26/2016 10:10:52 AM
This Little Biotech Could be a New Acquisition Target for Allergan (AGN) and Biogen (BIIB) 9/21/2016 6:21:34 AM
Will Biogen (BIIB)’s Alzheimer’s Drug Be a Miracle Drug or Just Another Bomb? 9/20/2016 6:30:25 AM
Biogen (BIIB) To Report Third Quarter 2016 Financial Results On October 26, 2016 9/15/2016 11:27:35 AM
AbbVie (ABBV) And Biogen (BIIB) Release: New Data Presented At ECTRIMS Reinforce Efficacy Of ZINBRYTA (Daclizumab) And Support Long-Term Safety Profile 9/15/2016 11:15:16 AM
Biogen (BIIB) Release: New Data Affirm Strong Efficacy And Well-Characterized Safety Profile Of TECFIDERA In Both Clinical Studies And Real-World Setting 9/14/2016 10:17:02 AM
Biogen (BIIB) Shows Off New Tecfidera Data in MS Trials 9/14/2016 6:38:37 AM
Advice for Biogen (BIIB): Take a Page Out of Biotech's Best Friend Celgene (CELG)'s Playbook 9/9/2016 6:48:48 AM
12345678910...
//-->